Adara Ventures Announces First Close of €100M AV4 Fund, Targeting Cybersecurity, AI & Digital Infrastructure
Adara Ventures, the European venture capital firm specialising in early-stage deep tech investments, today announced the first close of its fourth flagship fund, AV4, targeting €100 million in capital commitments. This new fund reinforces Adara’s commitment to delivering strong returns in strategic sectors, including cybersecurity, applied AI, digital infrastructure, hardware components, digital health, and space.
“We are immensely proud to announce the successful first close of AV4,” said Nico Goulet, Founding Partner of Adara Ventures. “Over the past nine months, we have secured in excess of €140 million in commitments across our fourth-generation funds. Alongside AV4, this includes Adara Ventures Energy (AVE), our first Pan-European fund dedicated to energy transition technologies. In one of the most challenging fundraising environments of the past 20 years, our strong DPI record, disciplined investment strategy, and focused fund model make AV4 a compelling opportunity for our limited partners.”
Goulet continued: “In a sector obsessed with unicorns, our philosophy has always been to maximise ‘dragons’—companies that return the entire fund. We are proud to have generated at least one dragon in each of our previous fund generations, with AV2 poised to rank among the top 5% of VC funds in Europe for its vintage.”
Since its inception in 2005, Adara Ventures has invested in over 50 pioneering companies across Europe and the U.S., achieving more than 10 notable exits. Adara is backed by over 130 limited partners, including institutional investors, pension funds, asset managers, high-net-worth individuals, and family offices. “We are especially proud to welcome new anchor investors in this first close, as well as a new generation of Adara portfolio founders investing as LPs — a true testament to the strength of our value proposition,” Goulet added.
Adara is now actively investing from AV4 and AVE, with plans to complete the first three investments in each fund within the first half of 2025. Both funds remain open to new investors.
About Adara Ventures
Adara Ventures partners with visionary founders who have strong vision, courage, and execution capabilities. Founded in 2005, the firm manages more than €350 million in assets. Adara’s portfolio focuses on early-stage companies with a European footprint, specialising in cybersecurity, data applications and infrastructure, hardware components, digital health, space and energy transition technologies. For more information, visit www.adara.vc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313203598/en/
Contacts
Media Contact
Ross Strachan
+34 914517070
info@adara.vc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Trust in Digital Services Declines, Finds Thales18.3.2025 10:00:00 EET | Press release
Thales, today announced the findings of its 2025 Digital Trust Index – Consumer Edition, revealing a universal decline in trust for digital services compared to this time last year. Across 13 different sectors, only insurance, banking and Government saw either their trust level remain unchanged or increase very slightly. When asked which sector they trusted with their personal data, not one sector reached above 50% approval. Thales surveyed over 14,000 consumers across 14 countries about their online relationship with brands and services, their privacy expectations, and how brands can earn their trust. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318397240/en/ ©Thales This decline in trust comes as nearly one in five (19%) have been informed that their personal data has been compromised in the past year. Consequently, 82% have abandoned a brand in the past 12 months due to concerns about how their personal data was bein
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support18.3.2025 10:00:00 EET | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. Since its launch, the fund has screened over 300 projects and made several key investments into new companies across Europe driving cutting-edge innovation in biotechnology. Among the newly established companies are BioClec, focused on breakthrough therapies for Alzheimer’s disease; Forth Therapeutics, a spin-out of the University of Edinburgh, which is advancing next-generatio
ATLAS Welcomes Strengthened Commitment to Increased Shareholder Returns from SES Board18.3.2025 09:43:00 EET | Press release
ATLAS Infrastructure (“ATLAS”) is a specialist listed infrastructure investor managing funds on behalf of long-term infrastructure clients. ATLAS’s actively managed accounts currently hold in aggregate a greater than 10% voting interest and 12.5% economic interest in SES S.A (“SES” or the “Company”). ATLAS supports the decision from the SES Board of Directors (“the Board”) to further strengthen Company governance through a modernisation of the Board structure and composition. Introducing further capital markets experience into a reduced Board of 9 increases alignment of stakeholder interests. ATLAS looks forward to continuing its engagement with the Board, the Nomination Committee and other Significant Stakeholders to assist with finding the best possible candidate during the upcoming selection process. Further, ATLAS welcomes the decision by the Board to endorse Shareholder Resolution 22 (“Resolution on Capital Return to Shareholders”) at the 2025 Annual General Meeting. The Board’s s
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy18.3.2025 08:00:00 EET | Press release
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases. “At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts18.3.2025 08:00:00 EET | Press release
Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/ The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asgar MD, Dr Samir Kapadia MD, and Dr Nicolas van Mieghem MD. The SAB is chaired by Dr Martin Leon, Professor of Medicine at New York’s Columbia University Irving Med
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom